Adverum Biotechnologies, Inc. (ADVM)

Adverum Biotechnologies Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	1	3.6	-	7.5	-
Revenue Growth (YoY)	-72.22%	-	-	-	-
Cost of Revenue	77.04	77.49	95.58	89.18	73.31
Gross Profit	-76.04	-73.89	-95.58	-81.68	-73.31
Selling, General & Admin	63.12	55.06	54.73	63.38	44.64
Operating Expenses	63.12	55.06	54.73	63.38	44.64
Operating Income	-139.16	-128.94	-150.31	-145.06	-117.95
Interest & Investment Income	8.23	5.75	2.67	0.58	1.56
EBT Excluding Unusual Items	-130.93	-123.19	-147.64	-144.48	-116.39
Merger & Restructuring Charges	-	-	-4.7	-	-
Asset Writedown	-	-	-2.12	-1.06	-
Pretax Income	-130.93	-123.19	-154.46	-145.54	-116.39
Income Tax Expense	-	-1.08	0.07	-	1.11
Net Income	-130.93	-122.12	-154.54	-145.54	-117.51
Net Income to Common	-130.93	-122.12	-154.54	-145.54	-117.51
Shares Outstanding (Basic)	20	10	10	10	9
Shares Outstanding (Diluted)	20	10	10	10	9
Shares Change (YoY)	96.21%	1.58%	1.24%	15.14%	32.83%
EPS (Basic)	-6.62	-12.11	-15.57	-14.85	-13.80
EPS (Diluted)	-6.62	-12.11	-15.57	-14.85	-13.80
Free Cash Flow	-92.85	-91.71	-119.91	-122.95	-91.14
Free Cash Flow Per Share	-4.69	-9.10	-12.08	-12.54	-10.70
Operating Margin	-13915.90%	-3581.72%	-	-1934.12%	-
Profit Margin	-13092.70%	-3392.11%	-	-1940.53%	-
Free Cash Flow Margin	-9285.00%	-2547.50%	-	-1639.39%	-
EBITDA	-135.51	-123.3	-143.78	-140.41	-113.79
D&A For EBITDA	3.65	5.64	6.53	4.65	4.16
EBIT	-139.16	-128.94	-150.31	-145.06	-117.95

Updated Apr 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q